Real-World Effectiveness and Safety of Anifrolumab in Egyptian Patients with Moderate-to-Severe Systemic Lupus Erythematosus: A Retrospective Multicenter Study. (PubMed, J Clin Med) - Sep 27, 2026 - "Glucocorticoid burden also declined, with oral glucocorticoid use falling from 95.0% to 83.8% (p = 0.021), median prednisone dose from 20 mg/day to 5 mg/day (p < 0.001), intravenous methylprednisolone use from 50.0% to 6.3% (p < 0.001), and 63.8% achieving prednisone doses ≤ 7.5 mg/day (p < 0.001). No serious adverse events were reported. Anifrolumab was associated with significant short-term improvement in clinical and laboratory disease activity, marked steroid sparing, and reduced flare burden in Egyptian patients with moderate-to-severe SLE, with acceptable short-term tolerability."
Clinical • Journal • Real-world evidence • Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus • CRP
|
|
Abeer Abdelmonem Shahba; Ahmed Yehia Ismaeel; Dina Shahin; Eiman Soliman; Eman F Mohamed; Enas S Zahran; Fatma Fayed; Gehad Maghraby; Kamel Heshmat Gado; Mai M Morsy; Maie Helal; Manal Tayel; Nehad Mohamed Elshatby; Nevine Mohannad; Rehab Elnemr; Samah A El Bakry; Samar Tharwat; Shereen Abdelsalam Olwan; Yasmine Abu Halawa
|